SEC Comment Letter 0000000000-24-008064 to Nuvation Bio Inc. (NUVB, NUVB-WT) (CIK 0001811063) (NUVB)
Nuvation Bio Inc. (NUVB, NUVB-WT) (CIK 0001811063)
Date: July 16, 2024 · CIK: 0001811063 · Accession: 0000000000-24-008064
AI Filing Summary & Sentiment
File numbers found in text: 001-39351
Letter
July 16, 2024 David Hung, M.D. President and Chief Executive Officer Nuvation Bio Inc. 1500 Broadway, Suite 1401 New York, NY 10036 Re:Nuvation Bio Inc. Preliminary Proxy Statement on Schedule 14A Filed May24, 2024 File No. 001-39351 Dear David Hung M.D.: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Melissa H. Boyd, Esq.
Show Raw Text
July 16, 2024
David Hung, M.D.
President and Chief Executive Officer
Nuvation Bio Inc.
1500 Broadway, Suite 1401
New York, NY 10036
Re:Nuvation Bio Inc.
Preliminary Proxy Statement on Schedule 14A
Filed May24, 2024
File No. 001-39351
Dear David Hung M.D.:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Melissa H. Boyd, Esq.